Can-Fite BioPharma American Depositary Shares
CANF
9 hedge funds and large institutions have $179K invested in Can-Fite BioPharma American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
29% more funds holding
Funds holding: 7 → 9 (+2)
7% more capital invested
Capital invested by funds: $168K → $179K (+$11.4K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.1K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$2.32K |
| 3 |
JP Morgan Chase
New York
|
+$1.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$849 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $87.5K | -$849 | -15 | -0.9% |
|
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $47.5K | +$2.32K | +41 | +5% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $31.9K | +$34.1K | +602 | New |
|
4
Fifth Third Bancorp
Cincinnati,
Ohio
| $7.95K | – | – | – |
|
5
National Bank of Canada
Montreal,
Quebec, Canada
| $1.48K | – | – | – |
|
6
Citigroup
New York
| $1.47K | – | – | – |
|
|
7
JP Morgan Chase
New York
| $1.22K | +$1.3K | +23 | New |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $140 | – | – | – |
|
|
TWC
9
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $67 | – | – | – |
|
CANF Hedge Fund Activity: Q3 2023 in Review
9 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2023, worth a combined $179K — up 6.8% from $168K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CANF positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.1K. The largest seller was Morgan Stanley, cutting an estimated $849.
- 9 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2023, up from 7 in Q2 2023.
- Funds reported $179K of Can-Fite BioPharma American Depositary Shares stock for Q3 2023, up 6.8% quarter-over-quarter.
- 2 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2023 and 0 closed out, a net change of +2 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2023 was Susquehanna International Group, an estimated $34.1K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2023 was Morgan Stanley, an estimated $849 sold.
Based on aggregated 13F filings for Q3 2023.